Semaglutide: Research Overview

Full name

N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl]-[Aib8,Arg34]GLP-1(7-37)

Molecular formula

C187H291N45O59

Molecular weight

4113.58 g/mol

Sequence / class

31-residue modified GLP-1(7-37) analog with Aib8 substitution and C18 fatty-acid side chain at Lys26

Receptor targets

GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor coupled to Gαs and downstream cAMP/PKA/EPAC2 signaling cascades

Research classification

Incretin receptor agonist research analog. Note: the approved pharmaceutical form is FDA-approved for specified clinical indications; the research-grade lyophilized reagent is supplied strictly for in vitro analytical use

PubChem CID

56843331

Semaglutide is a long-acting GLP-1 receptor analog built on the GLP-1(7-37) backbone with an aminoisobutyric-acid substitution at position 8 and a fatty-acid side chain attached at lysine 26. The molecular formula is C187H291N45O59 with a calculated mass of approximately 4113 daltons. The Aib8 substitution stabilizes the molecule against dipeptidyl-peptidase-4 cleavage in published biochemical studies, while the C18 fatty-acid moiety supports albumin binding that extends in vitro half-life relative to native GLP-1.

Published literature classifies semaglutide as an incretin mimetic research analog within the broader GLP-1 receptor agonist class. The compound engages the GLP-1 receptor, a class B G-protein-coupled receptor coupled to Gαs, with downstream signaling cascades that include cAMP accumulation, PKA and EPAC2 activation, and well-characterized β-cell signaling biochemistry in in vitro reporter systems.

Research published in the peer-reviewed literature has described semaglutide as a useful reference compound for in vitro receptor pharmacology because its extended functional half-life in cellular models allows desensitization kinetics and time-resolved signaling events to resolve cleanly over multi-hour assay windows. Investigators have used the peptide as a benchmark when characterizing newer GLP-1R agonists and dual- or tri-receptor research peptides under matched analytical conditions.

The research-grade lyophilized form supplied by PūrTONIX is intended strictly for in vitro analytical use. While an approved pharmaceutical formulation of the parent molecule exists and carries FDA approval for specified clinical indications, the research reagent supplied here is not formulated, sterilized, or characterized for human or veterinary administration and is sold solely as a laboratory analytical input.

Structure reference: Public domain chemical databases (PubChem CID 56843331).

Published in vitro applications describe semaglutide as a reference compound in GLP-1 receptor reporter assays, including HEK293 cell lines stably expressing GLP-1R, INS-1E β-cell models, and primary islet preparations used in published incretin signaling research. Cellular signaling research has used the analog to study cAMP accumulation kinetics, receptor desensitization timecourses, and β-arrestin recruitment biochemistry under controlled in vitro conditions.

Receptor-binding studies indicate that semaglutide produces sustained pathway activation across multi-hour in vitro timecourses, which has made it a useful comparator when benchmarking the analytical performance of newer dual GIP/GLP-1 and tri-receptor research peptides. Reporter EC50 measurements across single-receptor and dual-receptor cell lines have appeared in published comparative pharmacology research.

The published literature also describes semaglutide as an analytical probe for studying receptor internalization and trafficking biochemistry in cellular models, with fluorescence-microscopy and biochemical fractionation readouts used to characterize the kinetics of receptor handling following agonist exposure.

• [1]A study published in Diabetes, Obesity and Metabolism (2018) examined the receptor-binding profile of semaglutide against the GLP-1 receptor in publicly available in vitro reporter systems.
• [2]A study published in Molecular Metabolism (2020) investigated incretin receptor signaling kinetics using long-acting GLP-1 analogs as reference compounds in cellular assays.
• [3]A study published in Journal of Medicinal Chemistry (2015) described the analytical characterization and structural design rationale of long-acting GLP-1 receptor analogs.

The above represents a non-exhaustive summary of publicly available research. PūrTONIX does not endorse, validate, or make claims based on any referenced study.

Published chemical property data indicate that semaglutide is soluble in mildly alkaline aqueous buffer and in phosphate-buffered saline at standard assay concentrations. The lyophilized peptide is typically stored at -20°C under inert atmosphere, with reconstituted stocks held in single-use aliquots at 2-8°C for short-term in vitro use. Freeze-thaw cycles are minimized to preserve analytical reproducibility in receptor reporter assays.

Reconstitution in PBS or in assay-matched buffer is standard for in vitro receptor pharmacology work. Reverse-phase HPLC purity analysis, electrospray mass spectrometry for identity confirmation, and residual solvent screening per ICH Q3C guidance are analytical methods commonly used to characterize research-grade peptides.

Handling recommendations are based on published chemical property data and are intended for qualified laboratory personnel only.

Receptor reporter assays at sub-nanomolar agonist concentrations are particularly sensitive to deletion peptides and synthesis byproducts. Material characterized for high chromatographic purity, with batch-specific chromatograms and mass-spectral data, are the analytical floor at which published reference EC50 values can be reproduced cleanly across cellular model systems.